Pubblicazioni

Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis)  (2024)

Autori:
Gargiulo, L.; Ibba, L.; Malagoli, P.; Amoruso, F.; Balato, A.; Bardazzi, F.; Burlando, M.; Carrera, C. G.; Dapavo, P.; Dini, V.; Gaiani, F. M.; Girolomoni, G.; Guarneri, C.; Lasagni, C.; Loconsole, F.; Marzano, A. V.; Maurelli, M.; Megna, M.; Travaglini, M.; Costanzo, A.; Narcisi, A.
Titolo:
Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis)
Anno:
2024
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Lingua:
Inglese
Referee:
No
Nome rivista:
Journal of the European Academy of Dermatology and Venereology
ISSN Rivista:
0926-9959
Intervallo pagine:
946-949
Parole chiave:
Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis
Breve descrizione dei contenuti:
Apremilast is an oral inhibitor of phosphodiesterase (PDE)-4 that has been approved for the treatment of patients with moderate-to- severe plaque psoriasis who have contraindications or inadequate response to conventional systemic treatments. 1,2 It is also indicated for the management of adults with active psoriatic arthritis (PsA) who have failed or are intolerant to other disease-modifying antirheumatic drugs (DMARDs).1,2 In Italy, apremilast is reimbursed for patients with moderate-to- severe plaque psoriasis in case of inadequate response/intolerance to systemic treatments and those with contraindications to biological drugs.3 Despite the wide use of apremilast for the treatment of plaque psoriasis, long-term real-world experiences are still limited.4,5
Id prodotto:
142095
Handle IRIS:
11562/1144247
ultima modifica:
31 ottobre 2024
Citazione bibliografica:
Gargiulo, L.; Ibba, L.; Malagoli, P.; Amoruso, F.; Balato, A.; Bardazzi, F.; Burlando, M.; Carrera, C. G.; Dapavo, P.; Dini, V.; Gaiani, F. M.; Girolomoni, G.; Guarneri, C.; Lasagni, C.; Loconsole, F.; Marzano, A. V.; Maurelli, M.; Megna, M.; Travaglini, M.; Costanzo, A.; Narcisi, A., Long-term effectiveness and tolerability of apremilast in patients with moderate-to- severe plaque psoriasis: A 5-year multicentre retrospective study—IL PSO (Italian landscape psoriasis) «Journal of the European Academy of Dermatology and Venereology»2024pp. 946-949

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<indietro

Attività

Strutture

Condividi